By Felipe Burns, Cambrex
Securing end-to-end biopharmaceutical testing services has become increasingly challenging for biopharma companies at all stages of development and commercialization, who may need to overcome a lack of resources to conduct cGMP-compliant testing in-house, concerns about contamination at all-in-one facilities, and/or difficulty commanding personalized attention from large CDMO partners.
Partnering with a contract lab helps to ensure quality results by leveraging experienced testing professionals, freeing biopharma companies’ personnel to focus on their own core competencies or other projects. A contracted lab’s focus can remain 100 percent on analytical testing and counted upon as impartial, since that entity is not tied to production of the material. Additionally, a multitude of different modalities exist within the biopharmaceutical market and leveraging a single laboratory with aptitude in all those areas can be advantageous, regardless of whether the company is hyper focused in one area or has several drugs in the pipeline.
Cambrex’s broad reach in supporting small molecule analytics, large molecules, and cellular- and viral-based therapeutics positions us well to devise creative solutions to our clients’ problems. This includes, when necessary, applying new bioassays and technologies. By prioritizing the human element — embracing client challenges as our own — we ensure our experts are aligned and communicative with client teams. We combine that philosophy with a global network of state-of-the-art facilities to provide top-to-bottom integrated analytical support for clients as they move through different phases of their regulatory submission.